3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
14
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Refractory Solid Tumors
1
Liposarcoma
1
HR+HER2- Breast Cancer
1
Carcinoma, Transitional Cell
1
Interventions
Cyclophosphamide
25
fludarabine
19
Dexamethasone
17
pembrolizumab
13
Rituximab
12
venetoclax
9
Lenalidomide
9
Gemcitabine
9
Etoposide
9
pomalidomide
8
Vincristine
7
glofitamab
6
fludarabine phosphate
6
carfilzomib
6
Temozolomide
6
obinutuzumab
5
daratumumab
5
Prednisone
5
Nivolumab
5
Doxorubicin
5
Cisplatin
5
Calcium Dobesilate
5
Bortezomib
5
zanubrutinib
4
selinexor
4
Immunotherapy, Adoptive
4
Cytarabine
4
Carboplatin
4
Azacitidine
4
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
eribulin
×
90 days
×
Clear all
No trials found.